



Press release

NFL Biosciences publishes its 2025 financial agenda

Montpellier, France, March 5th, 2025, 5:45 p.m. CET – NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda for 2025.

Events	Dates *
2024 annual results	April 11 th 2025
Annual General Meeting (Montpellier)	June 25 th 2025
2025 half-year results	October 24 th 2025

**Press releases will be published after the close of the stock market*

The calendar is provided for information purposes only and may be subject to modification.

About NFL Biosciences: www.nflbiosciences.com

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL).

Contacts:

NewCap

Investors relations / Media relations

Mathilde Bohin / Arthur Rouillé

Tel.: +33 (0)1 44 71 94 94

E-mail: nfl@newcap.eu

NFL Biosciences

Bruno Lafont

Tél.: +33 (0)4 11 93 76 67

E-mail: info@nflbiosciences.com